|
1
|
Brake M, Loertzer H, Horsch R and Keller
H: Recurrence and progression of stage T1, grade 3 transitional
cell carcinoma of the bladder following intravesical immunotherapy
with bacillus Calmette-Guérin. J Urol. 163:1697–1701. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brake M, Loertzer H, Horsch R and Keller
H: Long-term results of intravesical bacillus Calmette-Guérin
therapy for stage T1 superficial bladder cancer. Urology.
55:673–678. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamm DL, van der Meijden PM, Morales A,
Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A and Debruyne
FM: Incidence and treatment of complications of bacillus
Calmette-Guérin intravesical therapy in superficial bladder cancer.
J Urol. 147:596–600. 1992.PubMed/NCBI
|
|
4
|
Lima L, Dinis-Ribeiro M, Longatto-Filho A
and Santos L: Predictive biomarkers of bacillus Calmette-Guérin
immunotherapy response in bladder cancer: Where are we now? Adv
Urol. 2012:2326092012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Azuma T, Nagase Y and Oshi M: Pyuria
predicts poor prognosis in patients with non-muscle-invasive
bladder cancer. Clin Genitourin Cancer. 11:331–336. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Echols RM, Tosiello RL, Haverstock DC and
Tice AD: Demographic, clinical, and treatment parameters
influencing the outcome of acute cystitis. Clin Infect Dis.
29:113–119. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mostofi FK, Sobin LH and Tosoni I:
Histological Typing of Urinary Bladder TumoursInternational
Histological Classification of Tumours, No 19. World Health
Organisation; Geneva: 1973
|
|
10
|
Nieder AM, Brausi M, Lamm D, O'Donnell M,
Tomita K, Woo H and Jewett MA: Management of stage T1 tumors of the
bladder: International Consensus Panel. Urology. 66:(Suppl 1).
108–125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hagemann T, Balkwill F and Lawrence T:
Inflammation and cancer: A double-edged sword. Cancer Cell.
12:300–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Millán-Rodríguez F, Chéchile-Toniolo G,
Salvador-Bayarri J, Palou J, Algaba F and Vicente-Rodríguez J:
Primary superficial bladder cancer risk groups according to
progression, mortality and recurrence. J Urol. 164:680–684. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zuiverloon TC, Nieuweboer AJ, Vékony H,
Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response
to bacillus Calmette-Guérin immunotherapy in high-risk bladder
cancer patients: A systematic review. Eur Urol. 61:128–145. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donskov F and von der Maase H: Impact of
immune parameters on long-term survival in metastatic renal cell
carcinoma. J Clin Oncol. 24:1997–2005. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ilie M, Hofman V, Ortholan C, Bonnetaud C,
Coëlle C, Mouroux J and Hofman P: Predictive clinical outcome of
the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell
ratio in patients with resectable nonsmall cell lung cancer.
Cancer. 118:1726–1737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hinotsu S, Akaza H, Isaka S, et al: BCG
Tokyo 172 Strain Study Group: Sustained prophylactic effect of
intravesical bacille Calmette-Guérin for superficial bladder
cancer: A smoothed hazard analysis in a randomized prospective
study. Urology. 67:545–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamm DL, Blumenstein BA, Crissman JD, et
al: Maintenance bacillus Calmette-Guérin immunotherapy for
recurrent TA, T1 and carcinoma in situ transitional cell carcinoma
of the bladder: A randomized Southwest Oncology Group Study. J
Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
